Enhertu Recommended for EU Approval in HER2-Positive Metastatic Solid Tumours

summarizeSummary

AstraZeneca's Enhertu has received a positive recommendation from the CHMP for EU approval in HER2-positive metastatic solid tumours, marking a potential first-in-class, tumour-agnostic indication.

check_boxKey Events

• EU Regulatory Recommendation

  The Committee for Medicinal Products for Human Use (CHMP) has recommended Enhertu for approval in the EU as a monotherapy for adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumours who have received prior treatment and have no satisfactory treatment options.

• Broad Tumour Agnostic Indication

  This recommendation is for a 'tumour agnostic' indication, meaning it applies across a broad range of HER2-positive solid tumours, including biliary tract, bladder, cervical, endometrial, ovarian, pancreatic, non-small cell lung, and colorectal cancers.

• Potential First-in-Class Therapy

  If approved, Enhertu would become the first HER2-directed therapy and antibody drug conjugate to receive a tumour agnostic indication in the EU, addressing a significant unmet medical need.

• Based on Positive Phase II Trials

  The positive opinion is based on clinically meaningful responses observed in a subgroup of patients with HER2-positive (IHC 3+) tumours across three Phase II trials: DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02.

auto_awesomeAnalysis

The CHMP's positive opinion for Enhertu represents a significant regulatory milestone, potentially opening up a broad new market in the EU for AstraZeneca and Daiichi Sankyo. The 'tumour agnostic' indication means Enhertu could be used across various HER2-positive solid tumours, addressing an unmet need where targeted treatment options are currently limited. This expands the drug's commercial potential beyond specific cancer types and reinforces its position as a leading oncology asset.